Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO and President John Cox executed a sale of 2,683 shares of the company's common stock on June 16, 2026. The transaction, valued at $49,179, involved shares sold at a weighted average price of $18.33, with individual transaction prices ranging from $18.00 to $18.70. This sale was part of a structured plan to meet tax withholding obligations tied to the vesting of restricted stock units originally granted to Mr. Cox on December 4, 2024. The transaction was automatic and consistent with a Rule 10b5-1 trading plan, indicating it was not a discretionary trade by Mr. Cox.
Post-transaction, Mr. Cox's direct holdings in Dyne Therapeutics stand at 368,151 shares, including 259,564 unvested restricted stock units. He also maintains indirect ownership of 72,000 shares distributed across four trusts established for his children's benefit.
Dyne Therapeutics has recently expanded its loan facility with Hercules Capital, increasing the total potential funding to $400 million. The company secured an additional $50 million immediately and has access to further tranches totaling $125 million, contingent upon meeting specific milestones. A final tranche of up to $75 million may also be available, subject to lender approval.
In clinical developments, Dyne has completed enrollment in the expansion cohort of its Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1, with plans to report topline data in early 2027. Additionally, Dyne has submitted a Biologics License Application to the FDA for its Duchenne muscular dystrophy treatment, zeleciment rostudirsen, seeking accelerated approval. The company has also launched its Phase 3 FORZETTO trial for the same treatment, aiming to enroll 90 participants.
These developments reflect Dyne's ongoing efforts in advancing its therapeutic programs and securing financial resources. The company maintains a strong balance sheet with more cash than debt and carries a FAIR financial health rating according to InvestingPro analysis.